Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation
by Evelyn Lepka de Lima, Ana Angélica Lindoso, Giovanna Mariah Orlandi, Suely Fukasava, Catia Martinez, Julio Croda, C. Robert Horsburgh Jr, Otavio Ranzani, Meredith B. Brooks, Jason R. Andrews Background Loss to follow-up (LTFU) during tuberculosis treatment is a major programmatic gap, but how much excess mortality it causes has been difficult to estimate, because individuals who disengage…
Tuberculosis treatment in Brazil revealed a significant loss of patients during the course, with follow-up gaps leading to excess deaths. A study of 171,048 individuals in São Paulo state between 2013 and 2023 found that 12.2% disengaged from treatment, with 65% having received directly observed therapy (DOT). Using a clone-censor-weight target trial emulation method, researchers compared two strategies, one allowing disengagement within the first six months and the other encouraging continuous care.
The analysis, adjusted for various factors including age, sex, race, and health conditions, showed that loss to follow-up increased standardized 5-year mortality by 2.49 percentage points. The highest absolute excess mortality was observed in people living with HIV, at 5.16 percentage points. The impact was most significant in younger, stably housed individuals, who generally had lower baseline mortality.
Despite high DOT coverage, the study emphasizes the importance of providing ongoing support to maintain treatment adherence and reduce mortality.
Rewritten by urgent.news; may contain errors — check the original.